jorge e cortes md, eha 2019 – advances in the treatment and management of acute myeloid leukaemia
Published 5 years ago • 216 plays • Length 6:31
Download video MP4
Download video MP3
Similar videos
-
4:15
jorge cortes, md, on the evolution of cml treatment, remaining challenges
-
2:36
asco24 direct highlights | jorge cortes, md
-
33:29
higher-risk mds and aml: how new guidelines are changing diagnosis, classification and management
-
5:10
jorge e cortes asco20: interim analysis of the phase ii optic trial of ponatinib in cp-cml
-
47:11
tackling unmet needs in chronic myeloid leukaemia: what’s next in the treatment algorithm?
-
7:02
jorge e. cortes, md
-
7:36
alexander perl, eha 2019 – the phase iii admiral trial
-
1:27
the safety and efficacy of grb2 inhibition with bp1001 in aml
-
5:33
leukemia, causes, signs and symptoms, diagnosis and treatment.
-
4:33
what is leukemia? - danilo allegra and dania puggioni
-
16:14
clinical clip from eha 2024
-
4:25
professor jorge e. cortes, m.d. - gilteritinib in the treatment of newly diagnosed flt3 aml
-
3:15
what is leukemia?
-
2:36
jorge cortes, md, shares data presented at ash 2017 regarding bosutinib in cml treatment
-
2:22
jorge cortes, md, on what was discussed at ash 2017 regarding treatment discontinuation in aml
-
0:16
how can real-world evidence guide the management of elderly & frail patients with multiple myeloma?
-
19:15
medscape perspectives | ash 2017 breakthroughs clinical trials
-
7:42
prof. cortes | glasdegib in combination with cytarabine & daunorubicin in untreated aml patients
-
9:21
brian jonas, asco20: venetoclax combination treatment in older patients with acute myeloid leukemia
-
1:53
asc2escalate: phase ii dose-escalation study of second-line asciminib in patients with cml-cp
-
5:07
jorge cortes | eha 2018 | highlights of the randomized phase iii quantum-r study
-
1:17
the efficacy of olutasidenib in aml following venetoclax failure
Clip.africa.com - Privacy-policy